{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', '11.5.', 'Appendix 5: Child-Pugh Classification', 'A participant is classified with mild hepatic impairment (Class', 'if their overall sum of', 'scores is', 'points, moderate hepatic impairment (Class ) if their overall sum of scores', 'is', 'points, and severe hepatic impairment (Class if their overall sum of scores', 'is', 'based on the Child-Pugh system [Pugh, 1973] scoring described in the following', 'table (Table 4). For participants requiring anticoagulation therapy, discussion with the', 'study medical monitor will be required.', 'Table 4', 'Child-Pugh System', 'Finding', 'Points Scored for Each Observed Finding', 'CCI', 'CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by', 'Athird party copyright laws and therefore have been excluded.', '[Pugh, 1973; Lucey, 1997]', 'References', 'Lucey MR, Brown KA, Everson GT, et al. Minimal criteria for placement of adults on', 'the liver transplant waiting list: a report of a national conference organized by the', 'American Society of Transplant Physicians and the American Association for the Study', 'of Liver Diseases. Liver Transpl Surg. 1997;3:628-37.', 'Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the', 'oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-49.', '101']['2017N331008_06', 'CONFIDENTIAL', '208090', '11.6.', 'Appendix 6: Prohibited Medications', 'The following concomitant medications or therapies are not permitted at any time during', 'the study:', 'HIV immunotherapeutic vaccines are not permitted at any time during the study.', 'Other experimental agents, antiretroviral drugs not otherwise specified in the', 'protocol, cytotoxic chemotherapy, or radiation therapy may not be administered.', 'Systemically administered immunomodulators (such as interleukin and interferon', 'agents) are prohibited (a list of examples is provided in the SRM). This includes', 'topical agents with substantial systemic exposure and systemic effects. Use', 'of', 'topical imiquimod is permitted.', 'For participants with an unanticipated requirement for HCV therapy during', 'study, interferon or any other medications that have a potential for adverse drug-', 'drug interactions with study intervention are prohibited during the conduct of the', 'study.', 'Acetaminophen (paracetamol) cannot be used in participants with acute viral', 'hepatitis [James, 2009].', 'The following medications or their equivalents may cause decreased concentrations of', 'DTG. Therefore, the following medications must not be administered concurrently with', 'DTG.', 'Carbamazepine', 'Oxcarbamazepine', 'Phenobarbital', 'Phenytoin', 'Rifampicin or rifapentine', \"St. John's wort (Hypericum perforatum)\", 'Dofetilide, pilsicainide and fampridine are prohibited as DTG may inhibit their renal', 'tubular secretion resulting in increased dofetilide, pilsicainide or fampridine', 'concentrations and potential for toxicity.', 'Any substrate of organic cation transporter 2 (OCT2), with a narrow therapeutic window', 'should not be administered concurrently with DTG containing products.', 'Note: Any prohibited medication should be discontinued for a minimum of two weeks or', 'a minimum of three half-lives (whichever is longer) prior to the first dose.', '102']['2017N331008_06', 'CONFIDENTIAL', '208090', 'For information on concurrent therapies and interactions suspected to be relevant to', 'other antiretroviral therapy in the CAR regimen, please consult the local prescribing', 'information.', 'References', 'James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee', 'WM. Pharmacokinetics of Acetaminophen-Adduct in Adults with Acetaminophen', 'Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.', '103']\n\n###\n\n", "completion": "END"}